Diplomat’s Jennifer Hagerman named president-elect of Michigan Pharmacists Association for 2014
FLINT, Mich. — Diplomat senior director of education and quality Jennifer Hagerman has been named as president-elect of the Michigan Pharmacists Association for 2014, the specialty pharmacy company said Wednesday.
Diplomat said members of the MPA had voted in Hagerman, who directs Diplomat’s training arm, Diplomat University, as well as overseeing the company’s quality assurance program and directing its Postgraduate Year One Pharmacy Residency Program.
"I am eager to continue Diplomat’s tradition of serving the pharmacy profession, enhancing the company’s strong ties with MPA and staying at the forefront of pharmacy issues as they relate to the state of Michigan," Hagerman said. "I believe strongly in the mission of MPA and look forward to serving as president-elect."
Ranbaxy Labs marks 20th year in Ukraine
GURGAON, India — Ranbaxy Labs is celebrating the 20th anniversary of its operations in Ukraine, the Indian generic drug maker said Wednesday.
The drug maker established a base in the eastern European country in 1993 and has since become the largest drug company in the market, whose value is estimated at $3.7 billion, according to the company. Ranbaxy’s products in Ukraine include branded and generic drugs.
"Ranbaxy has been providing high-quality, affordable generic medicines to the citizens of Ukraine for the last two decades, thereby supporting the government to bring down healthcare costs," Ranbaxy CEO and managing director Arun Sawhney said. "We remain committed to the Ukraine market and its people and will continue to operate for our paradigm of quality and patients first."
Perrigo seeks approval for generic version of Acanya
ALLEGAN, Mich. — Drug maker Perrigo has filed with the Food and Drug Administration for approval of a generic topical ointment for treating acne in adolescents and adults, the company said Wednesday.
Perrigo said it filed for approval of clindamycin phosphate and benzoyl peroxide gel in the 1.2%/2.5% strengths. The drug is used to treat acne in patients 12 years and older.
The drug is a generic version of Dow Pharmasciences’ Acanya gel, which has annual sales of about $122 million, according to Symphony Health Solutions. Perrigo said it notified Dow of the filing, to which Dow responded by filing suit against Perrigo in the U.S. District Court for the District of New Jersey, alleging patent infringement. Under the Hatch-Waxman Act of 1984, the suit puts an automatic stay of FDA approval on Perrigo’s product for 30 months, or until the companies settle the case.